Summary:
American Institute of Research is conducting a Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in
Subjects with Interstitial Cystitis/Bladder Pain Syndrome
Qualified Participants Must:
• Be Between 18 and 80 years of age
•
Consistently had symptoms of bladder pain in addition to urinary urgency and/or urinary frequency for more than 6 months
•
Have a clinical diagnosis, or history consistent with the diagnosis, of IC/BPS for >3 months but ≤20 years
•
Have Pelvic floor pain <7 out of 10
•
Have at least 8 urinary voids in a 24-hour period
Qualified Participants May Receive:
Study medication and medical care associated with the study at no cost as well as $50.00 for each completed visit.